Ontvang nu dagelijks onze kooptips!

word abonnee
Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
  • Word abonnee

  • Inloggen

    • Geen account? Registreren

    Wachtwoord vergeten?
Markt vandaag Koersen Forum Premium IEX Expert
Home  /  Forum  /  Koffiekamer  /  Intellia Therapeutics 2024

Koffiekamer« Terug naar discussie overzicht

Intellia Therapeutics 2024

Volgen
235 Posts
Pagina: «« 1 ... 7 8 9 10 11 12 »» | Laatste | Omlaag ↓
  3. Hoger Lager 29 april 2024 17:08
    Intellia Therapeutics, Inc.
    April 29, 2024 7:30 AM EDT
    Intellia Therapeutics to Present Updated Data from Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the EAACI Congress 2024
    Extended follow-up will include safety, kallikrein reduction and attack rate data, including number of patients who continue to be completely attack free through the latest follow-up
    Intellia to host investor webcast on Monday, June 3, at 8 a.m. ET
    CAMBRIDGE, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced the acceptance of an oral presentation from the Phase 1 portion of the ongoing NTLA-2002 Phase 1/2 study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2024, taking place May 31 – June 3 in Valencia, Spain. NTLA-2002 is an investigational in vivo CRISPR-based gene editing therapy in development as a single-dose treatment for hereditary angioedema (HAE), a rare genetic condition that leads to potentially life-threatening swelling attacks. The presentation will include updated safety and efficacy results from the Phase 1 study across all three dose cohorts (25 mg, 50 mg and 75 mg).

    Presentation Details

    Title: CRISPR-based gene editing of KLKB1 resulted in long-term plasma kallikrein protein reduction and decreased attack rate in patients with hereditary angioedema: Updated results from a phase 1 study

    Session: Breakthroughs in management of Hereditary Angioedema

    Date and Time: Sunday, June 2, 2024, from 8:30 – 10:00 a.m. CET

    Presenter: Hilary Longhurst, M.D., Ph.D., FRCP, FRCPath, Senior Medical Officer at Auckland District Health Board and Honorary Associate Professor at University of Auckland, New Zealand, the trial’s principal investigator in New Zealand
  8. forum rang 5 MisterBlues 3 juni 2024 17:46
    Intellia Therapeutics Announces Positive Long-Term Data from Ongoing Phase 1 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)

    Sun, Jun 2, 2024, 2:00 PM GMT+210 min read
    In this article:

    NTLA
    +9.49%

    Extended follow-up data reaching over two years in the earliest patients dosed reinforce the potential of NTLA-2002 to be a functional cure for people living with hereditary angioedema (HAE)

    Eight of 10 patients remain completely attack-free following the 16-week primary observation period through the latest follow-up, including patients with the most severe disease

    Single dose of NTLA-2002 led to a 98% mean reduction in monthly HAE attack rate, with an average follow-up of over 20 months across all patients

    100% of patients who discontinued prophylaxis treatment after NTLA-2002 remain free of chronic prophylaxis treatment

    Favorable safety and tolerability profile observed at all dose levels

    Intellia to host investor webcast on Monday, June 3, at 8 a.m. ET

    CAMBRIDGE, Mass., June 02, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced long-term data from the Phase 1 portion of the ongoing Phase 1/2 study of NTLA-2002. NTLA-2002 is an investigational in vivo CRISPR-based gene editing therapy in development as a single-dose treatment for hereditary angioedema (HAE), a rare genetic condition that leads to potentially life-threatening swelling attacks. The data were shared in an oral presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2024, being held May 31 – June 3 in Valencia, Spain.

    “These unprecedented data strengthen our view that NTLA-2002 could be a groundbreaking treatment for people living with hereditary angioedema,” said Intellia President and Chief Executive Officer John Leonard, M.D. “After a single dose of our investigational in vivo CRISPR-based therapy, patients experienced durable elimination of their attacks. We are thrilled to see that the majority of patients have been attack free for over 18 months or longer. These remarkable attack rate reductions have been consistent, even in patients with the most severe symptoms. At the same time, the data from these 10 patients continue to demonstrate a very favorable safety profile. These long-term data provide strong evidence that NTLA-2002 could be a one-time, potential functional cure for this debilitating and life-threatening disease.”

    finance.yahoo.com/news/intellia-thera...
  11. Forecast2006 27 juli 2024 19:30
    CAMBRIDGE, Mass., July 24, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that it awarded inducement grants on July 22, 2024 to its Executive Vice President and Chief Financial Officer, Edward Dulac, under Intellia's 2024 Inducement Plan as a material inducement to employment.

    The inducement grants consisted of non-qualified stock options to purchase 96,219 shares of Intellia's common stock with an exercise price of $25.33 per share, the closing price of Intellia's common stock as reported by Nasdaq on July 22, 2024, with 33% of the options underlying the option award vesting on the first anniversary of the grant date and the remainder vesting monthly thereafter until fully vested on the third anniversary of the grant date; time-based restricted stock units (RSUs) for 66,324 shares of Intellia's common stock, with one-third of the shares underlying the RSU award vesting on each of the three consecutive anniversaries of the grant date; performance-based RSUs for 33,162 shares of Intellia's common stock, with vesting criteria linked directly to Intellia's total stockholder return over a three-year period compared to the companies comprising the Nasdaq Biotechnology Index at the beginning of the performance period; and performance-based RSUs for 30,000 shares (at target) of Intellia's common stock, with vesting criteria linked directly to certain development milestones over a three-year period.

    All equity vesting is subject to Mr. Dulac's continued service as an employee of, or other service provider to, Intellia through the applicable vesting dates. All of the above-described awards were granted outside of Intellia's stockholder-approved equity incentive plans pursuant to Intellia's 2024 Inducement Plan, which was adopted by the board of directors in June 2024. The awards were approved by a majority of the independent directors of Intellia's board of directors as a material inducement to Mr. Dulac's entering into employment with Intellia in accordance with Nasdaq Listing Rule 5635(c)(4).

    About Intellia Therapeutics

    Intellia Therapeutics, Inc. (NASDAQ:NTLA) is a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies. The company's in vivo programs use CRISPR to enable precise editing of disease-causing genes directly inside the human body. Intellia's ex vivo programs use CRISPR to engineer human cells outside the body for the treatment of cancer and autoimmune diseases. Intellia's deep scientific, technical and clinical development experience, along with its people, is helping set the standard for a new class of medicine. To harness the full potential of gene editing, Intellia continues to expand the capabilities of its CRISPR-based platform with novel editing and delivery technologies. Learn more at intelliatx.com and follow us @intelliatx.

    Kind regards,
    Forecast
  16. Forecast2006 30 juli 2024 14:41
    Intellia Therapeutics krijgt toestemming om fase 1/2 klinische studie van NTLA-3001 te starten voor de behandeling van alfa-1-antitrypsinedeficiëntie

    NTLA-3001 is een potentiële eenmalige genbewerkingsbehandeling die de AAT-eiwitniveaus kan normaliseren en de progressie van longziekte geassocieerd met alfa-1-antitrypsinedeficiëntie (AATD) kan stoppen
    NTLA-3001 is Intellia's eerste volledig op CRISPR gebaseerde in vivo gerichte kandidaat voor geninbrenging om door te stromen naar de kliniek
    Op schema om de eerste patiënt in 2H 2024 te doseren
    CAMBRIDGE, Mass., 30 juli 2024 (GLOBE NEWSWIRE) - Intellia Therapeutics, Inc. (NASDAQ: NTLA), een toonaangevend genbewerkingsbedrijf in de klinische fase dat zich richt op het revolutioneren van de geneeskunde met op CRISPR gebaseerde therapieën, kondigde vandaag de goedkeuring aan van zijn Clinical Trial Application (CTA) door het Britse Medicine and Healthcare products Regulatory Agency (MHRA) om een fase 1/2-studie te starten ter evaluatie van NTLA-3001 voor de behandeling van alfa-1-antitrypsinedeficiëntie (AATD)-geassocieerde longziekte.

    NTLA-3001 is een baanbrekende in vivo op CRISPR gebaseerde kandidaat voor geninsertie die is ontworpen om na een eenmalige behandeling duurzaam functionele AAT-eiwitten op normale niveaus te produceren. We zijn verheugd om toestemming te krijgen om te beginnen met deze belangrijke first-in-human studie van NTLA-3001 voor mensen met AATD, zei Intellia President en Chief Executive Officer John Leonard, M.D. Bovendien dient deze studie om ons modulaire geninvoegingsplatform te valideren, dat we van plan zijn te gebruiken om nu aan te pakken.

    De fase 1/2-studie zal een internationale, multicenter, eenarmige, open-label studie zijn van NTLA-3001 bij volwassenen met AATD-geassocieerde longziekte. De studie omvat maximaal 30 patiënten en bestaat uit een dosis-escalatiefase, gevolgd door een dosis-expansiefase om de aanbevolen dosis te bevestigen. De studie zal de veiligheid, verdraagbaarheid, farmacokinetiek en farmacodynamiek van NTLA-3001 evalueren. Meer informatie over het onderzoek is te vinden op clinicaltrials.gov, indien beschikbaar.

    Voor meer info zie Investing.com

    Kind regards,
    Forecast

  18. Forecast2006 1 augustus 2024 16:00
    CAMBRIDGE, Mass., 01 augustus 2024 (GLOBE NEWSWIRE) - Intellia Therapeutics, Inc. (NASDAQ: NTLA), een toonaangevend genbewerkingsbedrijf in het klinische stadium dat zich richt op het revolutioneren van de geneeskunde met op CRISPR gebaseerde therapieën, zal zijn financiële resultaten en operationele hoogtepunten voor het tweede kwartaal van 2024 presenteren in een conferentiegesprek op 8 augustus 2024, om 8 uur ET.

    Deelnemen aan de oproep:

    Amerikaanse bellers moeten 1-833-316-0545 bellen en internationale bellers moeten 1-412-317-5726 bellen, ongeveer vijf minuten voor de call. Alle deelnemers moeten vragen om te worden verbonden met de Intellia Therapeutics conference call.
    Bezoek deze link voor een gelijktijdige live webcast van het gesprek.

    Een herhaling van de oproep zal beschikbaar zijn via de pagina Evenementen en Presentaties van de sectie Investors & Media op de website van Intellia op www.intelliatx.com, te beginnen op 8 augustus 2024 om 12.00 uur ET.

    Kind regards,
    Forecast
  20. Hoger Lager 4 augustus 2024 12:31
    quote:

    Forecast2006 schreef op 4 augustus 2024 10:02:

    [...]

    Halfjaarcijfers zijn uitgesteld naar 8 augustus.

    Maar wat in het vat zit verzuurd niet.
    Kind regards,
    Forecast
    Zo is het. Elk moment kan ook de data van fase 2 ntla-2002 naar buiten worden gebracht.

    En ook de goedkeuring van de FDA om met fase 3 te starten. Dan heeft intellia 2 blockbuster fase 3 trials lopen. En daarnaast nóg 5 veelbelovende projecten.
235 Posts
Pagina: «« 1 ... 7 8 9 10 11 12 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Markt Vandaag

Stijgers

instrument koers absoluut verschil relatief verschil
Galapagos 23,340 +0,88 +3,92%
Alfen N.V. 16,290 +0,45 +2,87%
Sligro 12,880 +0,34 +2,71%
HEIJMANS KON 26,500 +0,65 +2,51%
JUST EAT TAKEAWAY 13,445 +0,28 +2,09%
Fugro 22,840 +0,46 +2,06%
ForFarmers 3,055 +0,06 +2,00%
AMG Critical Materials N.V. 15,320 +0,30 +2,00%
SIGNIFY NV 21,720 +0,40 +1,88%
BAM 3,720 +0,07 +1,86%
AALBERTS NV 35,040 +0,62 +1,80%
Air France-KLM 7,644 +0,13 +1,70%
SBM Offshore 16,790 +0,27 +1,63%
Flow Traders 17,620 +0,26 +1,50%
FASTNED 16,460 +0,24 +1,48%
OCI 26,270 +0,37 +1,43%
Akzo Nobel 56,180 +0,78 +1,41%
Nedap N.V. 57,800 +0,80 +1,40%
ALLFUNDS GROUP 5,560 +0,07 +1,28%
IMCD 141,500 +1,75 +1,25%
KPN 3,608 +0,04 +1,23%
INPOST 16,590 +0,19 +1,16%
NN Group 43,930 +0,50 +1,15%
AMX 894,89 +10,00 +1,13%
UMG 23,350 +0,25 +1,08%
ArcelorMittal 20,850 +0,22 +1,07%
Eurocommercial Properties 23,750 +0,25 +1,06%
ING 15,982 +0,16 +1,02%
Kendrion 12,540 +0,12 +0,97%
Vopak 41,760 +0,38 +0,92%
ABN AMRO BANK N.V. 15,435 +0,14 +0,92%
CTP 17,120 +0,14 +0,82%
ASCX 1.212,98 +8,73 +0,72%
Wereldhave 14,200 +0,10 +0,71%
UNILEVER PLC 56,820 +0,40 +0,71%
RANDSTAD NV 43,380 +0,28 +0,65%
SHELL PLC 32,305 +0,19 +0,59%
JDE PEET'S 21,060 +0,12 +0,57%
WDP 24,740 +0,14 +0,57%
EXOR NV 98,200 +0,55 +0,56%
Arcadis 64,000 +0,35 +0,55%
Aperam 25,640 +0,14 +0,55%
PostNL 1,251 +0,01 +0,48%
Aegon 5,526 +0,03 +0,47%
ACOMO 17,760 +0,08 +0,45%
Basic-Fit 23,140 +0,10 +0,43%
TomTom 4,972 +0,02 +0,40%
Pharming 0,728 +0,00 +0,34%
TKH 36,860 +0,12 +0,33%
Heineken 79,800 +0,20 +0,25%
PROSUS 33,420 +0,08 +0,22%
Accsys 0,602 +0,00 +0,17%
EBUSCO HOLDING 0,986 +0,00 +0,15%
Ahold Delhaize 30,190 +0,04 +0,13%
Corbion 21,580 +0,02 +0,09%
AEX 908,56 +0,20 +0,02%
AZERION 1,460 0,00 0,00%
B&S Group SA 4,850 0,00 0,00%
Fagron 18,960 0,00 0,00%
Vastned 23,800 0,00 0,00%

Dalers

instrument koers absoluut verschil relatief verschil
BESI 119,550 -2,85 -2,33%
ASML 818,800 -14,20 -1,70%
ASMI 601,200 -10,20 -1,67%
RENEWI 7,910 -0,08 -1,00%
Van Lanschot Kempen NV 38,600 -0,35 -0,90%
THEON INTERNAT 11,400 -0,10 -0,87%
ASR Nederland 45,350 -0,26 -0,57%
NSI 19,700 -0,10 -0,51%
Sif Holding 11,940 -0,06 -0,50%
Avantium 2,250 -0,01 -0,44%
NX FILTRATION 4,960 -0,02 -0,40%
RELX 41,300 -0,16 -0,39%
DSM FIRMENICH AG 118,700 -0,45 -0,38%
ADYEN NV 1.326,000 -3,00 -0,23%
Philips Koninklijke 26,890 -0,06 -0,22%
Brunel 9,350 -0,02 -0,21%
Wolters Kluwer 150,850 -0,25 -0,17%
CM.COM 6,690 -0,01 -0,15%
vlag naam koers verschil relatief verschil
AEX 908,56 +0,20 +0,02%
AEX GR 3.548,07 +0,78 +0,02%
Germany40^ 18.626,80 +133,41 +0,72%
FTSE 100 8.327,78 +39,78 +0,48%
EURO50 4.903,56 0,00 0,00%
US30^ 41.167,80 0,00 0,00%
Nasd100^ 19.712,00 0,00 0,00%
US500^ 5.631,12 0,00 0,00%
Japan225^ 38.360,20 0,00 0,00%
VD-NEW 14,06 -0,86 -5,79%
#/^ Index indications calculated real time, zie disclaimer